Latest & greatest articles for insulin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on insulin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on insulin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for insulin

721. Glargine insulin for the treatment of type 1 and type2 diabetes

Glargine insulin for the treatment of type 1 and type2 diabetes Glargine insulin for the treatment of type 1 and type2 diabetes Glargine insulin for the treatment of type 1 and type2 diabetes Pichon Riviere A, Augustovski F, Ciapponi A, Cernadas C, Ferrante D, Regueiro A, Garcia Marti S Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation (...) Pichon Riviere A, Augustovski F, Ciapponi A, Cernadas C, Ferrante D, Regueiro A, Garcia Marti S. Glargine insulin for the treatment of type 1 and type2 diabetes. Ciudad de Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS) 2003 Authors' objectives The aim of this study was to summarise the available evidence on glargine insulin for the treatment of type 1 and type 2 diabetes. Authors' conclusions About 14% of diabetic patients would turn to basal insuline therapy

2003 Health Technology Assessment (HTA) Database.

722. Socioeconomic position in childhood and adulthood and insulin resistance: cross sectional survey using data from British women's heart and health study. Full Text available with Trip Pro

Socioeconomic position in childhood and adulthood and insulin resistance: cross sectional survey using data from British women's heart and health study. To assess the associations between childhood and adulthood social class and insulin resistance.Cross sectional survey.23 towns across England, Scotland, and Wales.4286 women aged 60-79 years.Insulin resistance and other cardiovascular disease risk factors.Belonging to manual social classes in childhood and in adulthood was independently (...) associated with increased insulin resistance, dyslipidaemia, and general obesity. The association between childhood social class and insulin resistance was stronger than that for adult social class. The effect, on insulin resistance and other risk factors, of belonging to a manual social class at either stage in the life course was cumulative, with no evidence of an interaction between childhood and adult social class. Women who were in manual social classes in childhood remained at increased risk

2002 BMJ

723. Birth weight of offspring and insulin resistance in late adulthood: cross sectional survey. Full Text available with Trip Pro

Birth weight of offspring and insulin resistance in late adulthood: cross sectional survey. To investigate the association between birth weight of offspring and mothers' insulin resistance in late adulthood.Cross sectional survey.General practitioner's surgeries in 23 towns in Great Britain.4286 women aged 60-79 years.Maternal insulin resistance.Birth weight of offspring was inversely related to maternal insulin resistance in late adulthood. For each 1 kg higher birth weight of offspring, women (...) had a 15% reduction in the odds of being in the fourth with highest insulin resistance, compared to other fourths (odds ratio 0.85; 95% confidence interval 0.71 to 1.00). This increased to 27% (0.73; 0.60 to 0.90) after adjusting data for potential confounders. A U shaped relation between birth weight of offspring and diabetes in older age was found; women with the lightest and heaviest offspring had the highest prevalence of diabetes.Birth weight of offspring is inversely related to the mother's

2002 BMJ

724. Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: a prospective observational study. (Abstract)

Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: a prospective observational study. Results of experimental and clinical studies suggest that insulin-like growth factor-I (IGF-I) and IGF binding protein-1 (IGFBP-1) could be important determinants of glucose homoeostasis. However, experimental models might also reflect compensatory and adaptive metabolic processes. We therefore prospectively examined the associations between circulating

2002 Lancet

725. Dairy consumption, obesity, and the insulin resistance syndrome in young adults: the CARDIA Study. (Abstract)

Dairy consumption, obesity, and the insulin resistance syndrome in young adults: the CARDIA Study. Components of the insulin resistance syndrome (IRS), including obesity, glucose intolerance, hypertension, and dyslipidemia, are major risk factors for type 2 diabetes and heart disease. Although diet has been postulated to influence IRS, the independent effects of dairy consumption on development of this syndrome have not been investigated.To examine associations between dairy intake

2002 JAMA

726. Summary for patients. Splitting the evening insulin dose to avoid low blood sugar levels and to improve sugar control in patients with type 1 diabetes. (Abstract)

Summary for patients. Splitting the evening insulin dose to avoid low blood sugar levels and to improve sugar control in patients with type 1 diabetes. 11926807 2002 04 23 2016 11 24 1539-3704 136 7 2002 Apr 02 Annals of internal medicine Ann. Intern. Med. Summary for patients. Splitting the evening insulin dose to avoid low blood sugar levels and to improve sugar control in patients with type 1 diabetes. I29 eng Clinical Trial Journal Article Patient Education Handout Randomized Controlled (...) Trial United States Ann Intern Med 0372351 0003-4819 0 Blood Glucose 0 Hypoglycemic Agents 0 Insulin 53027-39-7 Insulin, Isophane AIM IM Ann Intern Med. 2002 Apr 2;136(7):504-14 11926785 Adult Blood Glucose metabolism Circadian Rhythm Cross-Over Studies Diabetes Mellitus, Type 1 blood drug therapy Drug Administration Schedule Female Humans Hypoglycemia prevention & control Hypoglycemic Agents administration & dosage adverse effects Insulin administration & dosage adverse effects blood Insulin

2002 Annals of Internal Medicine Controlled trial quality: uncertain

727. From ugly fish to conquer death: J J R Macleod's fish insulin research, 1922-24. (Abstract)

From ugly fish to conquer death: J J R Macleod's fish insulin research, 1922-24. Fish insulin research had a very short heyday. Throughout most of 1922, production of insulin from livestock was difficult, erratic, and expensive. Although fish insulin was easy to extract and seemed to be a brilliant and logical solution to the shortage of insulin, collection of fish islets was a logistical nightmare. By the end of 1922, a scientist at the pharmaceutical company Eli Lilly in Indianapolis, IN, USA (...) had developed a way to concentrate and purify insulin by isoelectric precipitation. As a result of this breakthrough, the scales began to tip heavily in favour of livestock insulin. Nevertheless, research on commercial production of fish insulin continued for another 18 months but was finally abandoned.

2002 Lancet

728. Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. (Abstract)

Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lipodystrophy is a major side-effect of antiretroviral therapy but its pathophysiology remains elusive. In-vitro studies show that HIV-1-protease inhibitors affect adipocyte differentiation at an early step involving sterol-regulatory-element-binding-protein-1 (SREBP1), but in-vivo studies are lacking.We (...) of SREBP1c and downstream adipogenic factors. SREBP1c mRNA concentrations correlated negatively, and TNFalpha mRNA concentrations positively, with glycaemia and insulin resistance, but did not correlate with lipid variables.The altered differentiation status of peripheral adipocytes in HIV-1-infected patients with antiretroviral-induced lipoatrophy is associated with greatly reduced SREBP1c expression. Since the differentiation factor SREBP1 is rapidly targeted by protease inhibitors in vitro, our

2002 Lancet

729. Association between genetic variation in the gene for insulin-like growth factor-I and low birthweight. (Abstract)

Association between genetic variation in the gene for insulin-like growth factor-I and low birthweight. Low birthweight is associated with later risk of type 2 diabetes and related disorders. We aimed to show that a polymorphism in the gene for insulin-like growth factor-I, which has proved to raise risk of type 2 diabetes and myocardial infarction, is associated with low birthweight. We recorded birthweight and obtained DNA for 463 adults. Individuals who did not have the wild-type allele

2002 Lancet

730. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. (Abstract)

Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. Increased levels of asymmetric dimethylarginine (ADMA) are associated with endothelial dysfunction and increased risk of cardiovascular disease. Several cardiovascular risk factors are associated with reduced sensitivity to insulin, but elevated ADMA concentrations have not been fully linked to the metabolic syndrome.To evaluate the relationship between insulin sensitivity and plasma ADMA concentrations (...) , and to determine whether a pharmacological treatment that increases insulin sensitivity would also modulate ADMA concentrations.Cross-sectional study, containing a nonrandomized controlled trial component, of 64 healthy volunteers without diabetes (42 women, 22 men; 48 with normal blood pressure and 16 with hypertension), which was conducted at a university medical center between October 2000 and July 2001.Rosiglitazone (4 mg/d for 4 weeks and then 4 mg twice daily for 8 weeks), an insulin-sensitizing agent

2002 JAMA

731. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. (Abstract)

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Glucagon-like peptide 1 (GLP-1) has been proposed as a treatment for type 2 diabetes. We have investigated the long-term effects of continuous administration of this peptide hormone in a 6-week pilot study.20 patients with type 2 diabetes were alternately assigned continuous subcutaneous infusion of GLP-1 (n=10) or saline (n=10) for 6 (...) weeks. Before (week 0) and at weeks 1 and 6, they underwent beta-cell function tests (hyperglycaemic clamps), 8 h profiles of plasma glucose, insulin, C-peptide, glucagon, and free fatty acids, and appetite and side-effect ratings on 100 mm visual analogue scales; at weeks 0 and 6 they also underwent dexascanning, measurement of insulin sensitivity (hyperinsulinaemic euglycaemic clamps), haemoglobin A(1c), and fructosamine. The primary endpoints were haemoglobin A(1c) concentration, 8-h profile

2002 Lancet

732. Guidance on the use of long-acting insulin analogues for the treatment of diabetes û insulin glargine (TA53)

Guidance on the use of long-acting insulin analogues for the treatment of diabetes û insulin glargine (TA53) Guidance on the use of long‑acting insulin analogues for the treatment of diabetes – insulin glargine | Guidance | NICE Guidance on the use of long‑acting insulin analogues for the treatment of diabetes – insulin glargine Technology appraisal guidance [TA53] Published date: 06 December 2002 Last updated: 01 August 2015 Guidance This guidance has been replaced by . Explore © NICE [year

2002 National Institute for Health and Clinical Excellence - Technology Appraisals

733. Effects of diet and simvastatin on serum lipids, insulin, and antioxidants in hypercholesterolemic men: a randomized controlled trial. (Abstract)

Effects of diet and simvastatin on serum lipids, insulin, and antioxidants in hypercholesterolemic men: a randomized controlled trial. Limited information exists on the interaction between diet and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) and the interaction's effect on serum lipid and lipoprotein levels, insulin sensitivity, and circulating antioxidant vitamin and provitamin levels.To evaluate the separate and combined effects of diet and simvastatin therapy (...) ; triglycerides; apolipoprotein B; insulin; glucose; and antioxidants at week 12 of each treatment period, compared among the 4 groups.Dietary treatment decreased levels of total cholesterol by 7.6% (P<.001), LDL cholesterol by 10.8% (P<.001), HDL cholesterol by 4.9% (P =.01), apolipoprotein B by 5.7% (P =.003), serum insulin by 14.0% (P =.02), and alpha-tocopherol by 3.5% (P =.04). Simvastatin decreased levels of total cholesterol by 20.8%, LDL cholesterol by 29.7%, triglycerides by 13.6%, apolipoprotein B

2002 JAMA Controlled trial quality: predicted high

734. Effects of insulin in relatives of patients with type 1 diabetes mellitus. Full Text available with Trip Pro

Effects of insulin in relatives of patients with type 1 diabetes mellitus. It is unknown whether insulin therapy can delay or prevent diabetes in nondiabetic relatives of patients with diabetes.In a randomized, controlled, nonblinded clinical trial, we screened 84,228 first-degree and second-degree relatives of patients with diabetes for islet-cell antibodies; 3152 tested positive; 2103 of the 3152 underwent genetic, immunologic, and metabolic staging to quantify their risk; 372 of the 2103 had (...) a projected five-year risk of more than 50 percent; 339 of the 372 (median age, 11.2 years) were randomly assigned to undergo either close observation or an intervention that consisted of low-dose subcutaneous ultralente insulin, administered twice daily for a total dose of 0.25 unit per kilogram of body weight per day, plus annual four-day continuous intravenous infusions of insulin. Oral glucose-tolerance tests were performed every six months. Median follow-up was 3.7 years. The primary end point

2002 NEJM Controlled trial quality: uncertain

735. Effects of moderate alcohol intake on fasting insulin and glucose concentrations and insulin sensitivity in postmenopausal women: a randomized controlled trial. (Abstract)

Effects of moderate alcohol intake on fasting insulin and glucose concentrations and insulin sensitivity in postmenopausal women: a randomized controlled trial. Epidemiologic data demonstrate that moderate alcohol intake is associated with improved insulin sensitivity in nondiabetic individuals. No controlled-diet studies have addressed the effects of daily moderate alcohol consumption on fasting insulin and glucose concentrations and insulin sensitivity.To determine whether daily consumption (...) of low to moderate amounts of alcohol influences fasting insulin and glucose concentrations and insulin sensitivity in nondiabetic postmenopausal women.Randomized controlled crossover trial of 63 healthy postmenopausal women, conducted at a clinical research center in Maryland between 1998 and 1999.Participants were randomly assigned to consume 0, 15, or 30 g/d of alcohol for 8 weeks each as part of a controlled diet. All foods and beverages were provided during the intervention. An isocaloric

2002 JAMA Controlled trial quality: uncertain

736. Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trial. Full Text available with Trip Pro

Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trial. To evaluate whether a course teaching flexible intensive insulin treatment combining dietary freedom and insulin adjustment can improve both glycaemic control and quality of life in type 1 diabetes.Randomised design with participants either attending training immediately (immediate DAFNE) or acting as waiting list (...) control in people with type 1 diabetes without worsening severe hypoglycaemia or cardiovascular risk. This approach has the potential to enable more people to adopt intensive insulin treatment and is worthy of further investigation.

2002 BMJ Controlled trial quality: uncertain

737. Insulin pumps, conventional and intensive multiple injection insulin therapy for type 1 diabetes mellitus

Insulin pumps, conventional and intensive multiple injection insulin therapy for type 1 diabetes mellitus Insulin pumps, conventional and intensive multiple injection insulin therapy for type 1 diabetes mellitus Insulin pumps, conventional and intensive multiple injection insulin therapy for type 1 diabetes mellitus Oduneye F Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA (...) database. Citation Oduneye F. Insulin pumps, conventional and intensive multiple injection insulin therapy for type 1 diabetes mellitus. London: Bazian Ltd (Editors), Wessex Institute for Health Research and Development, University of Southampton 2002: 8 Authors' objectives This study aims to assess the effects of continuous insulin infusion pumps compared with multiple injection and conventional insulin therapy in people with type 1 diabetes mellitus. Authors' conclusions We found good evidence

2002 Health Technology Assessment (HTA) Database.

738. Protocol for outpatient screening and initiation of continuous subcutaneous insulin infusion therapy: impact on cost and quality

Protocol for outpatient screening and initiation of continuous subcutaneous insulin infusion therapy: impact on cost and quality Protocol for outpatient screening and initiation of continuous subcutaneous insulin infusion therapy: impact on cost and quality Protocol for outpatient screening and initiation of continuous subcutaneous insulin infusion therapy: impact on cost and quality Sanfield J A, Hegstad M, Hanna R S Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of an outpatient screening protocol to identify patients with Type I diabetes who would be suited for continuous subcutaneous insulin infusion (CSII), and who would continue the treatment for two and a half years. Type of intervention Screening

2002 NHS Economic Evaluation Database.

739. Glucose and insulin responses to dietary chromium supplements: a meta-analysis

Glucose and insulin responses to dietary chromium supplements: a meta-analysis Glucose and insulin responses to dietary chromium supplements: a meta-analysis Glucose and insulin responses to dietary chromium supplements: a meta-analysis Althuis M D, Jordan N E, Ludington E A, Wittes J T Authors' objectives To evaluate the effect of dietary chromium supplements on glucose and insulin response in healthy people and in people with glucose intolerance or type 2 diabetes. Searching The Cochrane (...) in nondiabetic patients was around 5 mmol/L. The primary studies included elderly, overweight people, athletes, participants in exercise or dietary interventions, people with mild forms of diabetes, people with atherosclerosis, and older African American women. Outcomes assessed in the review The inclusion criteria were not explicitly defined in terms of the outcomes. The outcomes assessed in the review were glucose and insulin concentration and glycated haemoglobin (HbA1c). Glucose and insulin concentration

2002 DARE.

740. Are there time and cost savings by using telemanagement for patients on intensified insulin therapy: a randomised, controlled trial

Are there time and cost savings by using telemanagement for patients on intensified insulin therapy: a randomised, controlled trial Are there time and cost savings by using telemanagement for patients on intensified insulin therapy: a randomised, controlled trial Are there time and cost savings by using telemanagement for patients on intensified insulin therapy: a randomised, controlled trial Biermann E, Dietrich W, Rihl J, Standl E Record Status This is a critical abstract of an economic (...) evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Telemanagement was compared with conventional outpatient management for patients on intensified insulin therapy. Telemanagement procedures permit the transfer of self-monitored blood glucose values, stored together with date and time in memory

2002 NHS Economic Evaluation Database.